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Abstract
AIM: The widespread use of antibacterial therapy has
been suggested to be the cause for the decline in the
prevalence of Helicobacter pylori infection. This study
examine the serial changes of urea breath test results
in a group of hospitalized patients who were given
antibacterial therapy for non-gastric infections.
METHODS: Thirty-five hospitalized patients who were
given antibacterial therapy for clinical infections,
predominantly chest and urinary infections, were
studied. Most (91 %) patients were given single
antibiotic of either a penicillin or cephalosporin group.
Serial 13C-urea breath tests were performed within 24
hours of initiation of antibiotics, at one-week and at
six-week post-therapy. H. pylori infection was
diagnosed when one or more urea breath tests was
positive.
RESULTS: All 35 patients completed three serial urea
breath tests and 26 (74 %) were H. pylori-positive. Ten
(38 %) H. pylori-infected patients had at least one
negative breath test results during the study period.
The medium delta 13C values were significantly lower
at baseline (8.8) than at one-week (20.3) and six-week
(24.5) post-treatment in H. pylori-positive individuals
(P=0.022). Clearance of H. pylori at six-week was only
seen in one patient who had received anti-helicobacter
therapy from another source.
CONCLUSION: Our results suggested that one-third of
H. pylori-infected individuals had transient false-
negative urea breath test results during treatment with
antibacterial agent. However, clearance of H. pylori
infection by regular antibiotic consumption is rare.
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INTRODUCTION
The rediscovery of Helicobacter pylori in 1984 had
revolutionized our understanding of gastroduodenal diseases [1].
This bacterium is now generally considered to be the most
important cause of  peptic  ulcer  diseases,  gastric
adenocarcinoma and MALT lymphoma of the stomach[2, 3].
Unless given appropriate antibiotic treatment, most infected
individuals will remain infected throughout their lifetime.
Spontaneous clearance of infection, particularly in adult, is
rare[4, 5].
     Interestingly, recent epidemiological studies suggest a
gradual reduction in the prevalence of H. pylori infection,
particularly in developed countries[4]. This decline in H. pylori
prevalence is accompanied by a parallel reduction in the
incidence of gastric carcinoma[6]. The reason for this decrease
remains unknown for the moment but widespread use of
antibiotics in the community has been speculated to be an
important cause for this decline. This study sought to determine
the serial changes of urea breath test in patients after taking
antibacterial agents given for conditions other than H. pylori
infection. The aim is to elucidate the effects of antibacterial
agents on urea breath test results and determine whether
antibacterial therapy given for concomitant infections would
result in clearance of H. pylori infection.
MATERIALS AND METHODS
Study design
Patients who were hospitalized for clinical infections, other
than gastrointestinal tract infection, and requiring the use of
antibiotics were recruited. The prescription of antibacterial
agent was at the discretion of the attending clinicians. Patients
were excluded if they were pregnant, had previous gastric
surgery, had previously received anti-helicobacter treatment,
or had been using acid-suppressive agents or antibiotics in the
recent six weeks. For all eligible patients, informed consent
was obtained from the patients or their parents. Since it is
unethical to delay or withhold anti-bacterial therapy, urea
breath test was performed as soon as possible but usually
performed after the initiation of the antibacterial agents. All
urea breath tests, however, should be performed within 24
hours of admission. Subsequent urea breath tests were repeated
at one-week and at six-week after the completion of antibiotics.
Drug history during the study period, including acid
suppressive therapies and antibiotics, was recorded. All patients
diagnosed with H. pylori infection were offered H. pylori
eradication therapy at the conclusion of this study. The study
protocol was approved by the Clinical Research Ethics
Committees of the Chinese University of Hong Kong and the
Kwong Wah Hospital of Hong Kong SAR.
13C urea breath test
13C-urea breath test (UBT) was performed in all patients, adult
or children, following the same protocol. All patients were
fasted for a minimum of four hours and were then given a
citric acid test meal to delay gastric emptying. A 75-mg 13C-
urea tablet dissolved in water was then given. Breath samples
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were collected before the test meal and 30 minutes after the
ingestion of the urea solution. Two devices, a 10-ml glass tube
and a sealed aluminum bag, were used for collection of exhaled
air. The difference in 13CO2 between the two breath samples
was analyzed by both the isotope ratio mass spectrometry
(Europa Scientific, Crewe, UK) and the infrared spectrometer
(FANci2, Fischer Analysen Instrumente, Leipzig, Germany).
A concordant delta 13CO2 value greater than 5 was regarded as
a positive result as described previously [7].
Determination of H. pylori infection status
Since none of these patients had indication for endoscopy, H.
pylori infection status was determined by the non-invasive urea
breath test. Patients were classified as H. pylori-positive when
one or more of the three consecutive breath test results tested
positive. This was based on the assumptions that urea breath
test was accurate in diagnosing H. pylori infection, and that
natural acquisition of H. pylori infections was extremely rare
[4,5].  Serology test (ASSURE; Genelabs Diagnostics,
Singapore) was used in patients with three consecutive
negative urea breath tests for the detection of IgG anti-
Helicobacter antibody to rule out the possibility of false
negative breath test results. This serology test has been
previously validated in our population[8].
Statistics
All statistical analysis was performed by GraphPad Prism
version 2.01 (San Diego, CA, USA). Comparisons of the delta
13C values among the three consecutive urea breath tests were
made by Kruskal-Wallis test. Post-hoc analysis was performed
by Dunn’s multiple comparison test.
RESULTS
Patients’ characteristics
A total of 35 patients were examined in this study (median
age=66 years, range 5-81; 13 male and 22 female). Two study
subjects were less than 18 years of age. The primary diagnoses
of these patients were chest infection (n=20), urinary tract
infection (n=12) and other infections (n=3). Thirty-two (91 %)
patients received a single antibiotic whereas three (9 %)
received two antibacterial agents during the hospitalization
period. All patients received a one- to two-week course of
standard dose penicillin (n=20) or cephalosporin (n=15) during
the study period. Intravenous route was initially given in 25
(71 %) patients whereas the rest received oral antibiotics
throughout the hospitalizations. One patient also received a
course of anti-Helicobacter therapy from his primary care
physicians during the follow up period.
Urea breath test
All 35 patients completed the three consecutive urea breath
tests. By using the pre-defined criterion, 26 (74 %) patients
were considered to be H. pylori-positive. None of the remaining
9 patients with negative breath tests had anti-Helicobacter
antibody detected.
      The serial breath test results of the study patients were given
in Table 1. Ten (29 %) H. pylori-positive patients had at least
one negative urea breath test results during the study period.
Of these 10 patients, 7 had the first test result negative whereas
the second and/or third test was (were) positive. Two patients
had a single negative test result at one-week post-treatment.
Among the 26 H. pylori-positive patients, only one was found
to have a negative test result at six-week post-antibiotic
treatment. However, this patient had been prescribed a one-
week course of proton-pump inhibitor-based triple therapy for
dyspepsia by his primary care practitioner two weeks after discharge
from hospital. It thus appeared that the apparent clearance of H.
pylori was attributed to the specific anti-Helicobacter therapy instead
of the first course of antimicrobial agent.
Table 1   Results of serial urea breath tests in the study patients
UBT
Baseline   1-wk post- 6-wk post-            No.of patients
antibacterial therapy antibacterial therapy
Neg Neg Neg          9
Neg Neg Pos          1
Neg Pos Pos          6
Pos Neg Pos          2
Pos Pos Neg         1*
Pos Pos Pos         16
Total         35
*This patient was given specific anti-Helicobacter therapy be-
tween second and third urea breath tests by his primary care
physicians. Pos=positive; Neg=negative
      For all H. pylori infected patients, the median delta 13CO2
values taken at baseline, one-week and six-week post-
treatment were 8.8, 20.3 and 24.5 respectively (P=0.022).
Post-hoc analysis showed that the median value measured at
baseline was significantly lower than at six-week post
treatment (P<0.05). On the other hand, the difference between
the first and second urea breath tests did not reach statistical
significance (Figure 1).
 13C
Figure 1  Changes in the delta 13C values (  13C ) of urea breath
tests after consumption of antibiotics in H. pylori-infected
patients. The broad line indicated the duration of antibiotics
consumption. A delta 13C value of greater than 5 was regarded
as a positive result. There was a significant difference between
the median delta 13C values taken at baseline, one-week and
six-week post treatment (P=0.022). Post-hoc analysis showed
that only the difference between the first and the third urea
breath tests reached statistical significance (P<0.05).
      All patients who had a transient negative urea breath test
result were given antibiotics by the intravenous route whereas
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10 (56 %) of the H. pylori-infected patients with persistent
positive breath test results received intravenous antibiotics (P
= 0.05). On the other hand, the choice and duration of antibiotic
therapy did not correlate with false negative breath test results.
DISCUSSION
Urea breath test is considered to be the best non-invasive test
for diagnosis of H. pylori infection, which is useful in both
diagnosis and post-treatment testing. However, it can be
potentially influenced by drugs that cause suppression of H.
pylori and hence, its urease activity. In this regard, the proton
pump inhibitor is the drug that is most extensively examined.
Laine et al showed that 33 % of H. pylori-infected patients
had a negative breath test result when receiving standard dose
of lansoprazole for the treatment of gastro-esophageal reflux
disease[9]. The breath test results returned positive in all patients
at 14-day after stopping the treatment. Although antibiotic
combinations are used in the treatment of H. pylori, the effect
of concomitant antibacterial agents given for other conditions,
usually single drug, on urea breath test results has not been
evaluated.
      In this study, we prospectively studied the serial changes
of urea breath tests in a small group of hospitalized patients
who were given antibiotics for infections other than H. pylori.
Despite the small number of patients examined, the results of
this study could provide insights into the effects of antibacterial
therapy on urea breath test results and hence H. pylori statuses
post-treatment. Unlike proton pump inhibitor with limited
choices and relatively well-defined standard doses, the choices
of antibiotics and the duration of therapy are highly variable.
Most of our study subjects suffered from chest or urinary tract
infections and were given a 1-2 week course of penicillin or
cephalosporin. As shown by our results, antibacterial agents
frequently (38 %) caused false-negative breath test results in
H. pylori-infected individuals. This was best illustrated by the
significantly lower delta 13CO2 value of first test results while
receiving antibacterial treatment. This transient suppression
occurred within 24 hours of antibiotics treatment and could
last for more than one-week post-treatment. Nevertheless, none
of the study subjects, except the one who had received specific
anti-Helicobacter treatment, had a persistent negative breath
test at 6-week.
    This observation is important for three reasons. First, the
widespread use of antibiotics in the community for various
infections have been speculated to be a major reason for the
decline in prevalence of H. pylori infection and possibly the
decline in gastric cancer incidences worldwide. This is
supported by a recent epidemiological study that demonstrated
a reduced risk of gastric cancer among patients who were given
antibiotic prophylaxis for hip replacement surgery[10]. Their
protective effect is presumably due to the serendipitous
eradication of H. pylori by the antibiotics, which leads to
subsequent reduction in the risk of development of gastric
cancer. However, if one looks into the rate of disappearance
of anti-Helicobacter antibody in patients who were given
antibiotics, it was not significantly higher than control
suggesting that the reduction in cancer incidences may not be
directly related to the clearance of H. pylori, at least from
serological point of view. In the present study, clearance of H.
pylori after a single course of antibiotic is rare. Despite the in
vitro sensitivity of H. pylori, the eradication rate of a single
standard dose of antibacterial agent is extremely low,
particularly with the use of penicillin and cephalosporin groups.
Previous data showed that the best single therapy for H. pylori
is clarithromycin[11]. Nonetheless, the use of two-week high
dose clarithromycin (2 gram per day) could only achieve
eradication of H. pylori in about one-third of the patients[11]. In
practice, the success of eradication is low without acid
suppressive agent such as proton pump inhibitors or bismuth
compounds[12]. The second importance of this study is the
potential risk of inducing acquired resistance with repeated
exposure to antimicrobial agent. Exposure of H. pylori to
antimicrobial agents without eliminating the bacteria poses a
major risk of inducing acquired resistance. This may offer a
plausible explanation for the rising incidence of antibiotic
resistance in countries where there is high consumption of
antibiotics[13-15]. The third reason for the importance of this
paper would be that treatment of antibiotics affect diagnostic
accuracy of UBT.
      The prevalence of H. pylori infection in this study (74 %)
is much higher than previously reported in local dyspeptic
patients. This is most likely due to random effect in study
involving small number of patients. Ideally, baseline urea
breath test should be performed prior to the administration of
antibiotics and biopsy-based diagnosis should be used for the
proper documentation of H. pylori status, but for ethnical
reasons, these problems are difficult to overcome. However,
we have performed serology tests in patients who had negative
urea breath tests to detect presence of anti-helicobacter
antibody. Thus, the chance of misclassifying H. pylori-positive
patient as negative would be minimal.
     In conclusion, this study showed that over one-third of
patients had a transient suppression of urease activity and
hence, false-negative urea breath test results during treatment
with antibacterial agents. This usually reverts back to normal
at six-week post treatment and thus, testing for H. pylori should
be postponed accordingly. On the other hand, spontaneous
clearance of H. pylori by antibacterial agent given for other
conditions is extremely rare, and could not account for the fall
in prevalence of H. pylori in most developed countries.
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